Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADO-5030 in Asthma Bronchoconstriction Challenge
NCT07281274Phase 1Not yet recruiting
- Sponsor
- Adovate
- Start
- Jan 2026
- Primary completion
- Jun 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADO-5030 in asthma, sponsored by Adovate. Primary endpoint: Provocative Concentration of Adenosine 5'-monophosphate causing a 20% fall in FEV1 at Day 1. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ADO-5030
03
Conditions
asthma
Beyond the preview
Go deeper on NCT07281274.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07281274.